Major Depressive Disorder, Antidepressant Treatment Response
Conditions
Keywords
Major depressive disorder, citalopram, pindolol, HDRS
Brief summary
The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.
Detailed description
Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram + placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected from a general hospital.
Interventions
DRUGPindolol
Pill orally administered. 15 mg/day t.i.d.
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a depressive episode * HDRS score \> 18 * Written informed consent
Exclusion criteria
* suicidal risk \> 3 * severe organic illness * other psychotropic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores on Hamilton Depression Rating Scale | 8 time points through 6 weeks |
Countries
Spain
Outcome results
None listed